The U.S. Food and Drug Administration's (FDA) chief says the agency will begin offering bonuses to drug reviewers who ...

Where FDA breakthrough devices stand through 2025: growth, authorizations, leading specialties, AI trends, and qualification pathways explained.

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed and Health Law Scan, focusing on issues impacting the rare disease community.

The plan raises a number of questions, including how the payments will be distributed across large teams of staffers.

On February 24, 2026, the U.S. Food and Drug Administration announced the establishment of new Produce Regulatory Program Standards (PRPS), developed in collaboration with the Nat ...

Many life sciences stakeholders are familiar with “traditional” designation programs operated by the Food and Drug Administration (FDA) in exercising its medical product authorities, such as the ...

WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...

Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr. Marty Makary, commissioner of the Food and Drug Administration, speaks in the Oval Office of the White House during an event ...

The FDA has suspended a quality control program for testing milk and dairy products, according to Reuters. The program is paused due to reduced lab capacity, and it’s unclear when it will resume.

April 22 (Reuters) - The U.S. Food and Drug Administration on Tuesday proposed speeding up medical device approvals for patients who have no other treatment options through a new program focused on ...

WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...